DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 22, 2024, regarding an event that occurred on February 15, 2024. The filing serves as a supplement to a previous report filed on February 21, 2024, concerning the acquisition of Twill, Inc. by DarioHealth Corp. (the "Company").
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references the inclusion of financial data in attached exhibits:
- Acquired Entity Financials: Audited financial statements of Twill, Inc. for the years ended December 31, 2023, and 2022 (Exhibit 99.1).
- Pro Forma Data: Unaudited pro forma combined financial statements of DarioHealth Corp. as of and for the year ended December 31, 2023 (Exhibit 99.2).
Material Changes
The primary material change reported is the completion of the acquisition of Twill, Inc. The Company, through its subsidiary TWILL Merger Sub, Inc., acquired all outstanding securities of Twill. This filing specifically adds the required pro forma financial information to the initial acquisition report.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies beyond the standard disclosure of the acquisition completion and the inclusion of financial exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 for Twill, Inc.'s audited financial performance for 2022 and 2023.
- Analyze Exhibit 99.2 for the unaudited pro forma combined financial statements to understand the impact of the acquisition on DarioHealth's financial position.
- Refer to the Initial Report filed on February 21, 2024, for a complete description of the acquisition terms and structure.
- Verify the integration status of Twill's operations with DarioHealth's existing business.